• 1
    Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187193.
  • 2
    Miyake N, Miyamoto S, Jarskog LF. New serotonin/dopamine antagonists for the treatment of schizophrenia. Clin. Schizophr. Relat. Psychoses 2012; 6: 122133.
  • 3
    Miyamoto S, Merrill DB, Lieberman JA, Feischhacker WW, Marder SR. Antipsychotic drugs. In: Tasman A , Maj M , First M , Kay J , Lieberman J (eds). Psychiatry, 3rd edn. John Wiley and Sons, Chichester, 2008; 21612201.
  • 4
    Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: Meta-analysis of Dopamine Active Transporter (DAT) density. Schizophr. Bull. 2013; 39: 2232.
  • 5
    Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [18F]/[11C] DOPA PET studies. Schizophr. Bull. 2013; 39: 3342.
  • 6
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373: 3141.
  • 7
    Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can. J. Psychiatry 1994; 39: 7484.
  • 8
    Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharm. Sci. 1999; 2: 3946.
  • 9
    Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 1990; 3: 127129.
  • 10
    Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335348.
  • 11
    Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A double-blind cross-over study. Br. J. Psychiatry 1995; 166: 241243.
  • 12
    Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J. R. Soc. Med. 2000; 93: 457462.
  • 13
    Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 2004; 161: 116124.
  • 14
    Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 1993; 16: 295312.
  • 15
    Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996; 153: 321330.
  • 16
    Harvey PD, Howanitz E, Parrella M et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. Am. J. Psychiatry 1998; 155: 10801086.
  • 17
    World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br. J. Psychiatry 1990; 156: 412.
  • 18
    Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004; 161: 156.
  • 19
    De Hert M, Wampers M, van Winkel R, Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res. 2007; 152: 165172.
  • 20
    Xiang YT, Wang CY, Si TM et al. Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry 2011; 44: 114118.
  • 21
    Hori H, Noguchi H, Hashimoto R et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 2006; 86: 138146.
  • 22
    Yoshio T, Uno J, Nakagawa M et al. Survey of the prescriptions for psychotherapy in Japanese inpatients with schizophrenia in 2006. Jpn. J. Clin. Psychopharmacol. 2010; 13: 15351545.
  • 23
    Yoshio T, Inada T, Uno J et al. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009. Hum. Psychopharmacol. 2012; 27: 7075.
  • 24
    Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 2009; 30: 148155.
  • 25
    Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000; 43: 43334353.
  • 26
    Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 2007; 12: 232246.
  • 27
    Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 2008; 117: 232243.
  • 28
    Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005; 10: 79104.
  • 29
    Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 1992; 260: 576580.
  • 30
    Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J. Clin. Psychopharmacol. 1989; 9: 347351.
  • 31
    Guthrie SK, Manzey L, Scott D, Giordani B, Tandon R. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers. J. Clin. Psychopharmacol. 2000; 20: 7783.
  • 32
    Potamianos G, Kellett JM. Anti-cholinergic drugs and memory: The effects of benzhexol on memory in a group of geriatric patients. Br. J. Psychiatry 1982; 140: 470472.
  • 33
    Drachman DA. Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 1977; 27: 783790.
  • 34
    McEvoy JP. A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J. Clin. Psychiatry 1987; 48 (Suppl.): 2023.
  • 35
    Ellis JR, Ellis KA, Bartholomeusz CF et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int. J. Neuropsychopharmacol. 2006; 9: 175189.
  • 36
    Perry EK, Perry RH. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995; 28: 240258.
  • 37
    Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtellotte WW, Potvin JH. Decreased verbal memory associated with anticholinergic treatment in Parkinson's disease patients. Int. J. Neurosci. 1981; 14: 6166.
  • 38
    Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson's disease. Arch. Neurol. 1982; 39: 666667.
  • 39
    Kurlan R, Como P. Drug-induced alzheimerism. Arch. Neurol. 1988; 45: 356357.
  • 40
    Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 1998; 12: 426445.
  • 41
    Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Natl Acad. Sci. U.S.A. 1999; 96: 1359113593.
  • 42
    Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J. Nerv. Ment. Dis. 2000; 188: 518524.
  • 43
    Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8: 457472.
  • 44
    Tomida K, Takahashi N, Saito S et al. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin. Neurosci. 2010; 64: 6269.
  • 45
    Woon PS, Chia MY, Chan WY, Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2010; 34: 463468.
  • 46
    Fayen M, Goldman MB, Moulthrop MA, Luchins DJ. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am. J. Psychiatry 1988; 145: 483486.
  • 47
    Chakos MH, Glick ID, Miller AL et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr. Serv. 2006; 57: 10941101.
  • 48
    Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry 1982; 139: 14601462.
  • 49
    Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am. J. Psychiatry 1986; 143: 230232.
  • 50
    McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr. Psychiatry 1989; 30: 135138.
  • 51
    Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 12091223.
  • 52
    Johnstone EC, Crow TJ, Ferrier IN et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol. Med. 1983; 13: 513527.
  • 53
    Singh MM, Kay SR, Opler LA. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: Implications for psychobiological subtyping. Psychol. Med. 1987; 17: 3948.
  • 54
    Dewey SL, Smith GS, Logan J et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl Acad. Sci. U.S.A. 1993; 90: 1181611820.
  • 55
    Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int. Clin. Psychopharmacol. 1996; 11: 199202.
  • 56
    Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br. J. Psychiatry 1983; 143: 584590.
  • 57
    Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 2002; 35: 611.
  • 58
    Drimer T, Shahal B, Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int. Clin. Psychopharmacol. 2004; 19: 2729.
  • 59
    Ogino S, Miyamoto S, Tenjin T et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2011; 35: 7883.
  • 60
    Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr. Bull. 1999; 25: 201222.
  • 61
    Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001; 158: 176184.
  • 62
    Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: Validation of the Japanese version. Psychiatry Clin. Neurosci. 2007; 61: 602609.
  • 63
    Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004; 68: 283297.
  • 64
    Klett CJ, Caffey E, Jr. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch. Gen. Psychiatry 1972; 26: 374379.
  • 65
    McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr. Scand. 1985; 71: 297303.
  • 66
    Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: A meta-analytic review. Neuropsychology 2009; 23: 315336.
  • 67
    Fusar-Poli P, Borgwardt S, Bechdolf A et al. The psychosis high risk state: A comprehensive state of the art review. JAMA Psychiatry 2013; 70: 107120.
  • 68
    Fusar-Poli P, Bechdolf A, Taylor M et al. At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr. Bull. 2013; 39: 923932.
  • 69
    Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: A meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012; 69: 110.
  • 70
    Fusar-Poli P, Yung A. Should attenuated psychosis syndrome be included in the DSM5? The debate. The Lancet 2012; 379: 591592.
  • 71
    Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr. Bull. 2011; 38: 12971307.
  • 72
    Fusar-Poli P, Borgwardt S, Crescini A et al. Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis. Neurosci. Biobehav. Rev. 2011; 35: 11751185.
  • 73
    Smieskova R, Fusar-Poli P, Allen P et al. Neuroimaging predictors of transition to psychosis – A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2010; 34: 12071222.
  • 74
    Fusar-Poli P, Perez J, Broome M et al. Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2007; 31: 465484.
  • 75
    Fusar-Poli P, Howes OD, Allen P et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: A multimodal imaging study. Arch. Gen. Psychiatry 2010; 67: 683691.
  • 76
    Fusar-Poli P, Howes OD, Allen P et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry 2011; 16: 6775.
  • 77
    Crossley NA, Mechelli A, Fusar-Poli P et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum. Brain Mapp. 2009; 30: 41294137.
  • 78
    Fusar-Poli P, Stone J, Broome M et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 2011; 68: 881890.
  • 79
    Howes O, Montgomery A, Asselin M et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009; 66: 1320.
  • 80
    McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: Diagnosis and drug discovery. Trends Pharmacol. Sci. 2008; 29: 9198.
  • 81
    Pukrop R, Schultze-Lutter F, Ruhrmann S et al. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J. Clin. Exp. Neuropsychol. 2006; 28: 13881407.
  • 82
    Niendam TA, Bearden CE, Johnson JK et al. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr. Res. 2006; 84: 100111.
  • 83
    Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 2006; 88: 2635.
  • 84
    Pflueger MO, Gschwandtner U, Stieglitz RD, Riecher-Rossler A. Neuropsychological deficits in individuals with an at risk mental state for psychosis – working memory as a potential trait marker. Schizophr. Res. 2007; 97: 1424.
  • 85
    Simon AE, Cattapan-Ludewig K, Zmilacher S et al. Cognitive functioning in the schizophrenia prodrome. Schizophr. Bull. 2007; 33: 761771.
  • 86
    Fusar-Poli P, Deste G, Smieskova R et al. Cognitive functioning in prodromal psychosis: A meta-analysis. Arch. Gen. Psychiatry 2012; 69: 562571.
  • 87
    McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991; 48: 739745.
  • 88
    Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs 2009; 23: 837855.
  • 89
    Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am. J. Psychiatry 1994; 151: 18191821.
  • 90
    Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr. Scand. Suppl. 1996; 389: 1217.
  • 91
    Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002; 57: 209219.
  • 92
    Miyamoto S, Fleischhacker WW. Pharmacological treatment of schizophrenia. In: Lauriello J , Pallanti S (eds). Clinical Manual for Treatment of Schizophrenia. American Psychiatric Publishing, Arlington, 2012; 291340.
  • 93
    Barnes TR. Comment on the WHO consensus statement: Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br. J. Psychiatry 1990; 156: 413414.
  • 94
    Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr. Scand. Suppl. 1994; 382: 2832.
  • 95
    Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011; 127: 8392.
  • 96
    Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J. Clin. Psychopharmacol. 2008; 28: 210213.
  • 97
    Kim B, Lee SH, Choi TK et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting. Prog. Neuropsychopharmacol Biol. Psychiatry 2008; 32: 12311235.
  • 98
    Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br. J. Psychiatry Suppl. 2009; 52: S63S67.
  • 99
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. J. Clin. Psychiatry 2009; 70: 13971406.
  • 100
    Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003; 64: 12501257.
  • 101
    Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003; 160: 11251132.
  • 102
    Gopal S, Berwaerts J, Nuamah I et al. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr. Dis. Treat. 2011; 7: 93101.
  • 103
    Kim SW, Shin IS, Kim JM et al. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum. Psychopharmacol. 2009; 24: 565573.
  • 104
    Rosenheck RA, Krystal JH, Lew R et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 2011; 364: 842851.
  • 105
    Pullen GP, Best NR, Maguire J. Anticholinergic drug abuse: A common problem? Br. Med. J. (Clin. Res. Ed.) 1984; 289: 612613.